StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3011% above fair value
$10.00+0.48 (+5.04%)

Close on Nov 20, 2026Market cap $1.40BP/E –Yield –

Intellia Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Intellia Therapeutics's gross profit for the twelve months ending Dec 31, 2019 was $43.10M, up 41.6% year over year. For fiscal 2021 it was $33.05M, down 43.0% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2021Dec 31, 2021$33.05M-43.0%
FY2020Dec 31, 2020$57.99M+34.5%
FY2019Dec 31, 2019$43.10M+41.6%
FY2018Dec 31, 2018$30.43M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019$10.94M+38.8%
Q3 FY2019Sep 30, 2019$10.62M+43.3%
Q2 FY2019Jun 30, 2019$11.12M–
Q1 FY2019Mar 31, 2019$10.43M–
Q4 FY2018Dec 31, 2018$7.88M–
Q3 FY2018Sep 30, 2018$7.41M–

More Intellia Therapeutics figures

See a number that looks wrong?